Лучшие больницы для «Vulvectomy» в Хайдарабад, Индия

The total cost of vulvectomy in India ranges from approximately USD 3,500 to USD 9,000, depending on the extent of surgery (wide local excision versus radical vulvectomy with groin lymphadenectomy and reconstructive flap), hospital tier (NABH-accredited versus JCI-accredited), and whether adjuvant procedures such as sentinel lymph node mapping with ICG fluorescence or concurrent pelvic lymphadenectomy are required. In the UAE (Dubai and Abu Dhabi), the equivalent procedure costs between USD 8,000 and USD 20,000 at JCI-accredited and DHA-licensed hospitals, reflecting the higher operational costs and premium clinical infrastructure of the region. Both ranges cover surgery, anesthesia, operating theater use, standard postoperative medications, nursing care, and routine in-hospital diagnostics. Additional costs — including adjuvant radiotherapy (typically USD 4,000–8,000 in India; USD 12,000–25,000 in the UAE), advanced reconstruction using myocutaneous flaps, or robotic-assisted pelvic node dissection — are quoted separately in the individualized treatment plan that GAF Healthcare prepares for each patient. India is typically 50–65% less expensive than the UAE for the same oncologic procedure and comparable surgical expertise, making it the most cost-effective destination globally for vulvectomy outside the patient's home country.

Most patients undergoing vulvectomy should plan to remain in the destination country for a minimum of 4 to 6 weeks before taking an international flight. The in-hospital phase lasts 5–10 days, during which surgical drains are removed, wound integrity is assessed, urinary catheter is discontinued, and preliminary pathology results are reviewed. The subsequent outpatient recovery phase (weeks 2–6) is critical: wound check and suture removal occur at the 2-week visit, and the 4-week visit confirms full epithelialization of the surgical site, absence of infection or wound breakdown, and clinical exclusion of deep vein thrombosis — which is a significant concern after pelvic and perineal surgery and during long-haul travel. Patients who require adjuvant radiotherapy (indicated for node-positive disease or positive surgical margins) will need to remain for an additional 5–6 weeks beyond surgery, extending total in-country stay to 10–12 weeks; in such cases, GAF Healthcare coordinates the radiotherapy schedule, accommodation, and visa extension concurrently. Fit-to-fly clearance is formally issued by the treating gynecologic oncologist after clinical assessment and, where indicated, compression Doppler ultrasound of the lower limbs to exclude DVT. Patients are advised to wear below-knee graduated compression stockings (15–20 mmHg) throughout the return flight and to ambulate in the cabin every 1–2 hours regardless of distance.

The success rate of vulvectomy is strongly stage-dependent and is most meaningfully expressed as the 5-year disease-specific survival rate. For FIGO Stage I (tumor confined to the vulva, ≤2 cm, with stromal invasion ≤1 mm — Stage IA — or >1 mm — Stage IB — and node-negative), 5-year survival rates range from 86% to 98% with adequate surgical margins. Stage II disease (tumor >2 cm or with adjacent spread, but lymph node-negative) achieves 5-year survival of approximately 77–85%. Node-positive disease (Stage III) has more variable outcomes: patients with a single small positive node achieve 5-year survival of around 60–70%, while those with bilateral or multiple positive nodes or extracapsular extension experience survival rates of 30–50%. The introduction of sentinel lymph node biopsy for early-stage disease has not only preserved survival outcomes equivalent to full groin dissection but has dramatically reduced surgical morbidity — particularly lymphedema — improving quality-of-life outcomes. At high-volume gynecologic oncology centers in India and the UAE partnered with GAF Healthcare, procedural technical success (clear surgical margins, R0 resection) is achieved in over 90% of appropriately selected cases. Postoperative complications such as wound dehiscence, while common (20–50% minor wound breakdown), are managed conservatively in most cases and do not negatively affect long-term oncologic outcomes. Recurrence rates depend on pathologic nodal status and margin status; adjuvant concurrent chemoradiotherapy in high-risk patients has been shown to reduce locoregional recurrence by approximately 50% compared to surgery alone.